Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 7/20 | 0.56 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.56 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21295779 | 0.81 | CYP2A6 (0.39) | CYP2A6CYP2B6CYP2E1CYP3A4CYP2C9 | |
| SCHEMBL21295870 | 0.80 | CYP2A6 (0.38) | CYP2A6CYP2B6CYP2E1CYP3A4CYP2C9 | |
| SCHEMBL610112 | 0.79 | ALDH1A1 (0.33) | — | |
| SCHEMBL5924659 | 0.76 | CYP2A6 (0.56) | CYP2A6CYP2B6CYP2E1CYP3A4CYP2C9 | |
| SCHEMBL3997707 | 0.74 | — | — | |
| SCHEMBL1510123 | 0.74 | ALDH1A1 (0.37) | CYP3A4CYP2C9 | |
| SCHEMBL17200847 | 0.74 | ALDH1A1 (0.37) | CYP3A4CYP2C9 | |
| SCHEMBL2125063 | 0.74 | CYP2A6 (0.72) | CYP2A6CYP2B6CYP2E1CYP3A4CYP2C9 | |
| SCHEMBL196071 | 0.73 | CYP2A6 (0.58) | CYP2A6CYP2B6CYP2E1CYP3A4CYP2C9 | |
| SCHEMBL149952 | 0.72 | CYP2A6 (1.00) | CYP2A6CYP2B6CYP2E1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | claimed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | claimed |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | claimed |
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | claimed |
| EP-3720858-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2020-10-14 | — | — | EP | claimed |
| CN-111699189-A | Modulators of beta-3 adrenergic receptors useful for the treatment or prevention of heart failure and disorders associated therewith | 艾尼纳制药公司 | 2020-09-22 | — | — | CN | claimed |
| WO-2019113359-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2019-06-13 | — | — | WO | claimed |
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | claimed |
| CN-102083794-A | Urea compounds as gamma secretase modulators | AMGEN INC | 2011-06-01 | — | — | CN | claimed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | claimed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | claimed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | claimed |
| WO-2004113365-A2 | HEPATITIS C SERINE PROTEASE TRI-PEPTIDE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| WO-2003051879-A1 | KNOWN AND NOVEL 4,5-DIHYDRO-IMIDAZO[4,5,1-IJ]QUINOLIN-6-ONES USEFUL AS POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2003-06-26 | — | — | WO | claimed |
| EP-0821665-B1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LAB (US) | 2001-10-04 | — | — | EP | claimed |
| US-6258813-B1 | BIOLOGICAL RECEPTORS WITH TETRAHYDROPIPERIZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT (DE) | 2001-07-10 | — | — | US | claimed |
| US-5831115-A | CYCLOBUTANECARBOXAMIDES | ABBOTT LABORATORIES (US) | 1998-11-03 | — | — | US | claimed |
| EP-0821665-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | Abbott Laboratories (US) | 1998-02-04 | — | — | EP | claimed |
| WO-1996033159-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-10-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | CYP2A6 2815/4885CYP2B6 2949/4885CYP2E1 2995/4885 |
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | CYP2A6 756/4885CYP2B6 788/4885CYP2E1 1190/4885 |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | CYP2A6 319/4885CYP2B6 312/4885CYP2E1 209/4885 |
| US-20110166132-A1 | Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | CYP2A6 3205/4885CYP2B6 3856/4885CYP2E1 4540/4885 |
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | CYP2A6 788/4885CYP2B6 831/4885CYP2E1 1231/4885 |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | CYP2A6 788/4885CYP2B6 831/4885CYP2E1 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.